BioSpace News Archive

selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T-cell mediated autoimmune diseases, announced positive results from the first-in-human Phase 1b trial of its lead compound, si-544, in atopic dermatitis patients.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET.

Theravance Biopharma, Inc. will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024.

Repertoire® Immune Medicines announced that it has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases.

Ocugen, Inc. announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phase 1/2 clinical trial at the Retinal Cell and Gene Therapy Innovation Summit being held May 3, 2024 in Seattle, WA.

Pfizer Inc. highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4 in Chicago.

Allarity Therapeutics, Inc. today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC’s Office of General Counsel (“Nasdaq”).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA ® HD (aflibercept) Injection 8 mg.

Prime Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for PM359, submitted on March 29.

Kraig Biocraft Laboratories, Inc., announces that it has signed key agreements with the Lam Dong Agro-Forestry Research Experiment Center, the sericulture authority in central Vietnam, pertaining to the rearing and breeding of the Company’s specialized silkworm.